Ntrk2 is also targeted, less selectively by other RTKi’s in the clinic or in early stage clinical development e.g. Lestaurtinib (for neuroblastoma;[42]) and PLX7486 (pancreatic adenocarcinoma; ClinicalTrials.gov identifier: NCT01804530). The gene discussed is NTRK2; the disease is pancreatic adenocarcinoma.